Biomea Fusion doses first patient in OPAL obesity study
Biomea Fusion says the first patient has been dosed in its OPAL study evaluating icovamenib in combination with semaglutide in obesity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.